MGF (Mechano Growth Factor)

MGF (Mechano Growth Factor) is the synthetic C-terminal E-peptide of the IGF-1Ec splice variant — a mechano-sensitive isoform of the IGF-1 gene specifically upregulated in skeletal muscle, cardiac muscle, and other tissues in response to mechanical strain, exercise, and injury. MGF represents the research tool for studying the mechano-sensitive arm of IGF-1 axis biology that is distinct from the systemic liver-produced IGF-1 responsible for most anabolic signalling.

The IGF-1 gene generates multiple isoforms through alternative splicing of exons 4, 5, and 6. The most important distinction is between IGF-1Ea (systemic, liver-produced under GH stimulation, the Ea E-peptide is rapidly cleaved to release free mature IGF-1) and IGF-1Ec (human) or IGF-1Eb (rodent) — the mechano-sensitive isoform generated in mechanically stressed tissues through a frameshift in exon 5 producing a unique C-terminal E-peptide. This Ec/Eb E-peptide is the sequence supplied as MGF and is not present in the systemic IGF-1 isoform.

Yang and Goldspink (FEBS Letters, 2002) published the landmark finding that MGF E-peptide promoted satellite cell (muscle stem cell) proliferation in a manner separable from IGF-1 receptor-mediated effects — establishing MGF as a research tool for studying mechano-sensitive muscle stem cell biology through mechanisms independent of the classical IGF-1R/PI3K/Akt/mTOR anabolic cascade. The separation of these two biological activities — IGF-1R-mediated anabolism (studied with IGF-1 LR3) and MGF E-peptide-mediated satellite cell activation (studied with MGF) — is the central research rationale for maintaining both compounds in the toolkit.

Satellite cells are the resident muscle stem cell population beneath the basal lamina of individual muscle fibres, normally maintained in quiescence by Notch signalling and other quiescence-maintaining signals. Following mechanical damage or intense exercise, MGF is upregulated locally and proposed to signal to satellite cells through a mechanism that may involve nuclear localisation of the E-peptide — a receptor-independent intracellular mechanism distinct from the extracellular IGF-1/IGF-1R ligand-receptor interaction. This satellite cell activation drives Pax7+ quiescent cells into active myogenic proliferation (Pax7+/MyoD+ activated satellite cells) and subsequent differentiation (myogenin+, MHC+) to form new myofibres or fuse with existing damaged fibres.

Practical pharmacokinetic considerations: native MGF E-peptide has an extremely short plasma half-life (estimated minutes) due to its small size enabling rapid renal filtration and susceptibility to serum proteases. This short half-life is advantageous for acute defined exposure experiments but limits systemic distribution and chronic research paradigms — for which PEG MGF (Signal Labs, available separately) provides the extended-stability alternative.

For satellite cell isolation and MGF research: human primary satellite cells can be isolated from skeletal muscle biopsy by enzymatic digestion (collagenase/dispase) and FACS sorting on CD56+/CD34-/CD45- population. Culture on Matrigel-coated plates in Ham's F10 + 20% FBS + bFGF (2.5ng/mL) for expansion. For differentiation, switch to DMEM + 2% horse serum. MGF E-peptide (1-100nM) applied during the proliferative phase (before differentiation medium switch) examines satellite cell activation effects; applied during differentiation examines effects on myogenic commitment. Compare with IGF-1 LR3 (same concentration range) to dissect IGF-1R-mediated versus E-peptide-specific biology. MW: approximately 2.8 kDa. Reconstitute in bacteriostatic water at 1mg/mL. Store lyophilised at -20°C. For laboratory and analytical research purposes only.